Calidi Biotherapeutics (CLDI)
Develops systemic oncolytic-virus platforms that deliver therapeutic payloads into tumors.
Something off on this page? Send us feedback.
Develops investigational oncolytic-virus platforms for cancer, led by RedTail, which is designed to circulate to metastatic sites, replicate selectively in tumor cells, and produce therapeutic payloads locally.
Develops RedTail, an extracellular-enveloped vaccinia-virus platform designed for systemic delivery to metastatic solid tumors. Its lead candidate is intended to replicate selectively in tumor cells and express an immune-stimulating payload in the tumor microenvironment; other RedTail programs explore in-situ T-cell engagers. NeuroNova and SuperNova are legacy platforms that use stem-cell carriers for high-grade glioma and intratumoral solid tumors.
Operates from San Diego, with research, process-development, and assay work supplemented by academic partners, CROs, and CDMOs in the United States, Germany, and Australia. Every candidate remains investigational, and evidence for RedTail’s systemic delivery and payload expression remains preclinical. Owns no commercial manufacturing facility and has no long-term supply arrangements with outside manufacturers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.1M · Total debt $1.9M · Total assets $7.2M · Shareholders' equity $3.1M
- Revenue
- $0
- Operating income
- −$4.2M
- Net income
- −$4.2M
No dividends on record.
| Institutions | 7.13% | 32.9K shares | |
|---|---|---|---|
| 24 holders · as of Jun 30, 2026 | |||
| Other | 92.87% | 427.6K shares | |
| remainder | |||
460.4K company shares as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (2.58M in the company's Sep 23, 2026 report, 460.4K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 1.55% | 114,550 | as of Jun 30, 2026 |
Hightower Advisors, LLCInstitution | 1.13% | 83,523 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.74% | 54,274 | as of Jun 30, 2026 |
Independent Advisor AllianceInstitution | 0.61% | 45,000 | as of Jun 30, 2026 |
RS Crum Inc.Institution | 0.59% | 43,239 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Genelux
Systemic vaccinia rival in metastatic lung and other solid tumors.
- Oncolytics Biotech
Intravenous oncolytic-virus rival across metastatic solid tumors.
- Replimune Group
Armed HSV rival in oncolytic-immunotherapy combinations.
- Candel Therapeutics
Locally delivered viral-gene-therapy rival in solid tumors.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Calidi Biotherapeutics | $1.09 | −1.80% | $511.1K | — | — | — | — |
| Genelux | $2.52 | −3.45% | $117.0M | — | — | 14,629.2 | −98.2% |
| Oncolytics Biotech | $0.6750 | −5.37% | $71.6M | — | — | — | — |
| Replimune Group | $12.83 | −4.75% | $1.13B | — | — | — | — |
| Candel Therapeutics | $11.63 | −1.90% | $868.3M | — | — | — | — |
| Median | — | — | 14,629.2 | −98.2% |